Methods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1
作者： Daniel Plano , Verónica Alcolea , Carmen Sanmartín , Arun K. Sharma
DOI: 10.1080/13543776.2017.1315103
关键词:
摘要: ABSTRACTIntroduction: Colorectal cancer (CRC) is the fourth most common worldwide. Targeted therapy drugs (TTDs) are a valid treatment, epithelial growth factor receptor (EGFR) inhibitors being one of commonly used for CRC patients. However, this treatment only useful patients with wild-type KRAS (wtKRAS) and effective on about 40 to 60% subset due high plasticity ErbB network.Areas covered: The invention proposes use protein levels dimer formation as biomarkers selecting, predicting monitoring showing sensitivity action EGFR benefit from combination HER2 inhibitors. in vitro data Lim1215 cells suggest over-activation HER3 signaling pathway response monotherapy; or MEK reversed activation.Expert opinion: To assess clinical applicabi...
elsevier.com
sci-hub.se 参考文章(53)
Christopher J. Torrance, Peta E. Jackson, Elizabeth Montgomery, Kenneth W. Kinzler, Bert Vogelstein, Allan Wissner, Maria Nunes, Philip Frost, Carolyn M. Discafani, Combinatorial chemoprevention of intestinal neoplasia. Nature Medicine. ,vol. 6, pp. 1024- 1028 ,(2000) , 10.1038/79534
Kihyun Kim, Sun-Young Kong, Mariateresa Fulciniti, Xianfeng Li, Weihua Song, Sabikun Nahar, Peter Burger, Mathew J. Rumizen, Klaus Podar, Dharminder Chauhan, Teru Hideshima, Nikhil C. Munshi, Paul Richardson, Ann Clark, Janet Ogden, Andreas Goutopoulos, Luca Rastelli, Kenneth C. Anderson, Yu-Tzu Tai, Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. British Journal of Haematology. ,vol. 149, pp. 537- 549 ,(2010) , 10.1111/J.1365-2141.2010.08127.X
Alexandra Canonici, Merel Gijsen, Maeve Mullooly, Ruth Bennett, Noujoude Bouguern, Kasper Pedersen, Neil A O’Brien, Ioannis Roxanis, Ji-Liang Li, Esther Bridge, Richard Finn, Dennis Slamon, Patricia McGowan, Michael J. Duffy, Norma O’Donovan, John Crown, Anthony Kong, Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. ,vol. 4, pp. 1592- 1605 ,(2013) , 10.18632/ONCOTARGET.1148
Emad Y. Moawad, Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel Journal of Gastrointestinal Cancer. ,vol. 46, pp. 380- 389 ,(2015) , 10.1007/S12029-015-9761-9
Anthony Kong, Katharina Feldinger, Profile of neratinib and its potential in the treatment of breast cancer Breast Cancer. ,vol. 7, pp. 147- 162 ,(2015) , 10.2147/BCTT.S54414
Vincent A. Pollack, Catherine DiOrio, April Theleman, Elsa G. Barbacci, Leslie R. Pustilnik, Mark Neveu, Mikel P. Moyer, Kenneth K. Iwata, Lee Arnold, Michael J. Morin, James D. Moyer, Bruce Boman, Penny Miller, Ann Cunningham, Margaret M. Reynolds, Don Sloan, Jonathan Doty, Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase Cancer Research. ,vol. 57, pp. 4838- 4848 ,(1997)
D. T. Dudley, L. Pang, S. J. Decker, A. J. Bridges, A. R. Saltiel, A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 92, pp. 7686- 7689 ,(1995) , 10.1073/PNAS.92.17.7686
Carolyn M. Discafani, Marion L. Carroll, M.Brawner Floyd, Irwin J. Hollander, Zaheed Husain, Bernard D. Johnson, Douglas Kitchen, Michael K. May, Madhu S. Malo, Albert A. Minnick, Ramaswamy Nilakantan, Ru Shen, Yu-Fen Wang, Allan Wissner, Lee M. Greenberger, Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785) Biochemical Pharmacology. ,vol. 57, pp. 917- 925 ,(1999) , 10.1016/S0006-2952(98)00356-6
Jeff B Smaill, Brian D Palmer, Gordon W Rewcastle, William A Denny, Dennis J McNamara, Ellen M Dobrusin, Alexander J Bridges, Hairong Zhou, HD Hollis Showalter, R Thomas Winters, Wilbur R Leopold, David W Fry, James M Nelson, Veronika Slintak, William L Elliot, Billy J Roberts, Patrick W Vincent, Sandra J Patmore, None, Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. Journal of Medicinal Chemistry. ,vol. 42, pp. 1803- 1815 ,(1999) , 10.1021/JM9806603
Jacques Ferlay, Hai-Rim Shin, Freddie Bray, David Forman, Colin Mathers, Donald Maxwell Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. ,vol. 127, pp. 2893- 2917 ,(2010) , 10.1002/IJC.25516